Bixiye
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2016
Natiijooyinka Raadinta
Soo bandhiga 3231 - 3240 ee natiijooyinka 4130
Bixiye
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
Taariikhda uu dhaqangalayo barnaamijka: Okt 10, 2016
Bixiye
P56-17 Implementation of a Medical Drug Exclusions List
Taariikhda uu dhaqangalayo barnaamijka: Okt 16, 2017
Bixiye
P5R1-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
Taariikhda dhaqangalka Barnaamijka: Jul 05, 2017
Bixiye
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2016
Bixiye
P53-16 New Notification Requirement for Outpatient Dialysis Services for Commercial Products and Subscribers in Government Programs
Taariikhda uu dhaqangalayo Barnaamijka: Nov 09, 2016
Bixiye
P43R1-16 Updated: Third Party Payments of Premium and/or Cost-Sharing
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2016
Bixiye
P6-17 A New Drug, Emflaza (deflazacort), Will Require Prior Authorization
Taariikhda uu dhaqangalayo Barnaamijka: 27, Feb 2017
Bixiye
P46-16 Changes in Medical Policy IV-87 Spinal Fusion: Lumbar
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 30, 2016
Bixiye
P17-17 Addition of Drug Kisqali to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 28, 2017